Stephen B Hanauer

Stephen B Hanauer is the Clifford Joseph Barborka Professor of Medicine in the Division of Gastroenterology and Hepatology at Northwestern University's Feinberg School of Medicine. A board-certified gastroenterologist at Northwestern Memorial Hospital, he is a globally recognized authority on inflammatory bowel disease (IBD) with expertise spanning clinical practice, research leadership, and national policy development.

His academic foundation includes:

• MD from University of Illinois, Chicago (1977)
• Internal Medicine Internship at University of Chicago (1978)
• Internal Medicine Residency at University of Chicago (1980)
• Gastroenterology Fellowship at University of Chicago (1982)

Dr. Hanauer's research pioneers advancements in Crohn's disease and ulcerative colitis management, focusing on biologic therapies, precision dosing, and treatment optimization. His work bridges clinical trials with real-world evidence to establish evidence-based standards for IBD care, significantly influencing therapeutic guidelines and healthcare utilization patterns.

His 2025 publications reveal a concentrated focus on biologic agent efficacy (anti-TNF therapies, infliximab, vedolizumab) and corticosteroid protocols through systematic reviews and real-world studies. These works emphasize precision medicine approaches and demonstrate his leadership in translating complex clinical data into actionable treatment frameworks for IBD.

His exceptional contributions are recognized through prestigious honors including:

• AGA IMIBD Mentorship Award (2025)
• Lifetime Mentor and Teaching Award, ACG (2021)
• Master of the American College of Gastroenterology (2020)
• Great Teacher Award, NIH (2020)
• Healio Award for Lifetime Disruptor in IBD (2019)
• Berk/Fise Award for Clinical Achievement (2018)
• Inspirational Physician Award, AMA (2014)

As a master educator and mentor, Dr. Hanauer has shaped generations of gastroenterologists through formal teaching roles and leadership in national educational initiatives. His research is amplified through strategic affiliations with the Center for Human Immunobiology, NUCATS, and Simpson Querrey Institute for Epigenetics, driving collaborative innovation in IBD pathophysiology and treatment.